1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
25.27 USD   +2.97%
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
21.51(c) 22.09(c) 23.53(c) 24.54(c) 25.27(c) Last
363 476 373 485 204 758 238 295 345 477 Volume
0.00% +2.70% +6.52% +4.29% +2.97% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -166 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,92x
Yield 2022 -
Sales 2023 3,33 M - -
Net income 2023 -170 M - -
Net Debt 2023 - - -
P/E ratio 2023 -9,01x
Yield 2023 -
Capitalization 1 474 M 1 474 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 442x
Nbr of Employees 89
Free-Float 85,6%
More Financials
Company
Vaxcyte Inc. is a clinical-stage vaccine company focused on developing vaccines to protect humankind from the consequences of bacterial diseases. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG. The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent,... 
More about the company
Ratings of Vaxcyte, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D
More Ratings
All news about VAXCYTE, INC.
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
05/09Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
04/20INSIDER SELL : Vaxcyte
MT
04/18VAXCYTE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/12TRANSCRIPT : Vaxcyte, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2..
CI
04/07INSIDER SELL : Vaxcyte
MT
04/05Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
AQ
04/04Vaxcyte Initiates Dosing in Second Part of Phase 1/2 Trial of VAX-24 in Invasive Pneumo..
MT
04/04Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinica..
GL
04/04Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 P..
CI
03/14INSIDER SELL : Vaxcyte
MT
More news
News in other languages on VAXCYTE, INC.
05/09Vaxcyte, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/07VENTE D'INITIÉS : Vaxcyte
04/04Vaxcyte commence à administrer la deuxième partie de l'essai de phase 1/2 du VAX-24 dan..
04/04Vaxcyte, Inc. annonce l'administration de doses aux premiers participants de la partie ..
02/28Vaxcyte, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre 2..
More news
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 25,27 $
Average target price 48,50 $
Spread / Average Target 91,9%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.6.22%1 431
GILEAD SCIENCES, INC.-12.99%78 068
REGENERON PHARMACEUTICALS, INC.5.71%70 575
VERTEX PHARMACEUTICALS19.24%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745